Figure 1 - Voxzogo Treatment Improves Body Proportionality From Year 1 Through Year 4Source: Company dataFigure 2 - Real-World Data Show High Adherence to Voxzogo TreatmentSource: Company data; Wedbush researchFigure 3 - BMRN Continues to Pursue Major Additional Opportunites for VoxzogoSource: Comp
Moody's Ratings (Moody's) said that Gilead Sciences, Inc.'s ("Gilead"; A3 positive) acquisition of Arcellx will improve Gilead's product and therapeutic diversity through full ownership of its key cell therapy pipeline product anito-cel for multiple myeloma. Gilead announced on 23 February that it e...
Arcus Biosciences (RCUS) Feb. 28, 2026: Additional ARC-20 data including activity and biomarker analysis of cas in ccRCCAscendis Pharma (ASND) Feb. 28, 2026: PDUFA date for TransCon CNP for pediatric achondroplasiaBioMarin Pharmaceutical (BMRN) Feb. 28, 2026: PDUFA date for Palynziq for adolescent
A director at Merck & Co Inc sold 10,000 shares at 121.456USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Coterra Energy Inc. (CTRA - $28.06) and Devon Energy Corp. (DVN - $39.94)News Reports Companies Near Potential Tie-Up to Create $60 Billion US Shale Group. According to the Financial Times, CTRA and DVN are in advanced talks about a combination that would create one of the largest oil and natural g
A director at Gilead Sciences Inc sold 10,000 shares at 139.891USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.